prostate%20cancer
PROSTATE CANCER

Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Supportive Therapy

Pharmacological Therapy

  • Mitoxantrone may be used for patients with symptomatic metastatic castration-resistant prostate cancer (CRPC) who have contraindications to Cabazitaxel or Radium-223 therapy
  • Denosumab and bisphosphonates (Eg Alendronate, Pamidronate, Zoledronic acid) may be suggested in patients with metastatic castration-resistant prostate cancer (CRPC) with bone metastasis to help prevent bone fractures, metastases, and other skeletal complications

Radiation Therapy

  • Recommended dose:
    • Non-vertebral metastases: 800 cGy x 10 fractions
    • Widespread bone metastases: Sr-89 or Sm-153 with or without focal external beam radiation therapy (EBRT)

Referral

  • Refer patient and his family to facilities that can provide palliative care services that can assist both the patient and his family while dealing with prostate cancer
  • Referral to pain clinics or palliative care team may also help in the symptomatic management of prostate cancer patients
Editor's Recommendations
Most Read Articles
24 Jan 2018
Women with neuropathic bladder (NB) and paediatric lower urinary tract reconstruction (LUTR) are at increased risk of developing complications during pregnancy and caesarean delivery (CD), with those having prolonged labour, prior CD or a history of noncompliance having the worst complications, according to a study.